Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Palbociclib (Primary)
- Indications Nervous system neoplasms
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 03 Apr 2017 Planned number of patients changed from 40 to 55.
- 03 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Dec 2018.